What Akrikhin does

Akrikhin (AO AKRIKHIN) is a Russian pharmaceutical manufacturer founded in 1936 and headquartered in Staraya Kupavna, Moscow Oblast, where it operates a single modern, GMP-certified production complex and an in-house R&D center. The company produces more than 200 pharmaceutical preparations spanning dermatology, cardiology, endocrinology, neurology, pediatrics, urology/nephrology, and gynecology, distributed under both proprietary brand names (Akriderm, Akvadetrim, Fitolizin, Komfoderm, Akrivario, etc.) and the МНН-Акрихин generic sub-brand, alongside a growing line of biologically active dietary supplements (BADs).

Its underlying technology is built on GMP-compliant pharmaceutical manufacturing and proprietary formulation capability, including development of polycomponent (combination) drugs and a 50-product R&D pipeline with 10+ commercial launches annually. Akrikhin has shifted R&D investment up roughly sixfold in recent years and is pursuing first-in-class candidates such as a non-hormonal topical for psoriasis and atopic dermatitis. The portfolio is GMP-certified and recognized through the GxP-Profi 2025 program and Eurasian Academy of Proper Practices quality awards.

The company monetizes a diversified domestic revenue base: (1) prescription and OTC generic drug sales through Russian pharmacy chains, independent pharmacies, and online channels such as uTeka.ru; (2) Russian government procurement under the ZhNVLP framework, where over 100 SKUs are listed (roughly 40–50% of the portfolio), providing stable federal and regional demand; and (3) contract manufacturing for third-party pharmaceutical partners using its GMP-certified capacity. The business is exclusively Russian-domestic, privately held, and led by President Denis Chetverikov.

Name

Akrikhin

Legal name

Akcionernoye obshchestvo «Khimeksko-farmatsevticheskiy kombinat «AKRIKHIN» (АО «АКРИХИН»)

Website

https://akrikhin.ru

Company type

Private

Founded year

1936

Operating status

Operating

Headcount range

101–250 employees

Short description

Akrikhin is a Russian pharmaceutical manufacturer founded in 1936 that produces 200+ generic and combination drugs across seven therapeutic areas from a GMP-certified plant in Staraya Kupavna, distributing through pharmacies, government ZhNVLP procurement, and contract manufacturing for domestic partners.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD), Specialty Care Pharmaceuticals (HLAIAAAB), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)

Keywords

• Generic pharmaceuticals
• Pharmaceutical manufacturing
• Prescription medicines
• OTC medications
• Dietary supplements

Headquarters

HQ city

Moscow

HQ country

Russia

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Personnel

Revenue model

1. Generic pharmaceutical sales (prescription and OTC): Akrikhin generates revenue through the sale of generic pharmaceutical products — both prescription (retsepturnye) and over-the-counter (bezretsepturnye) drugs — across its portfolio of 200+ preparations. Products include branded generics under the МНН-Акрихин label and branded product lines such as Akriderm, Akvadetrim, Fitolizin, Komfoderm, and others. Revenue is distributed across multiple therapeutic areas including dermatology, cardiology, neurology, and endocrinology.
2. Government procurement (ЖНВЛП): A significant share of revenue comes from supplying essential medicines included in the Russian ЖНВЛП (Vital and Essential Medicines list). Approximately 40–50% of the drug portfolio is covered by this list, securing stable government procurement contracts. Over 100 of the 200+ preparations are on ЖНВЛП.
3. Contract manufacturing: Akrikhin offers contract manufacturing services leveraging its GMP-certified production facilities, attracting partners seeking high-quality local production capacity. The company explicitly markets its production capabilities to potential partners via [email protected].
4. BADy (Dietary supplements) sales: Akrikhin manufactures and sells biologically active dietary supplements including Menoril, Normobakt L, SuperOptic, and Fitolizin PRENATAL through pharmacy channels.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Core offering

Akrikhin manufactures and sells a portfolio of more than 200 generic and branded pharmaceutical preparations (prescription and OTC) spanning seven therapeutic areas: dermatology, cardiology, vitamin D supplementation, endocrinology, neurology, pediatrics, and cosmetology. More than 100 of these products are on the Russian ZhNVLP (Vital and Essential Medicines) list, securing government procurement contracts. The company also offers GMP-certified contract manufacturing services to other pharmaceutical companies seeking production capacity in Russia.

Product overview

Akrikhin is a leading Russian pharmaceutical company founded in 1936, operating a GMP-certified manufacturing complex in Staraya Kupavna, Moscow Oblast. The company produces a broad portfolio of over 200 generic and OTC medications organized around seven therapeutic areas: dermatology (led by the Акридерм corticosteroid line and Микозорал antifungal), cardiology (Гипосарт and Капозид antihypertensives, Эспиро eplerenone), endocrinology/diabetology (Ситаглиптин + Метформин combination, Глидиаб, Глимекомб, Fordigliz, Инсудайв insulin products), neurology (Фонтурацетам nootropic, Баклосан muscle relaxant), pediatrics (Бронхо-Ваксом immunostimulant, Динобутин GI gel), urology/nephrology (Фитолизин in paste/capsule/БАД forms, Фитолизин PRENATAL, Фитолизин nefroCAPS), and gynecology (Овипол Клио estrogen, Клиндацин antibiotic). The portfolio is distributed across two main branding tracks: proprietary branded drugs (Acriderm, Akvadetrim, Fitolysin) and the МНН-Акрихин generic sub-brand. The company holds GMP certification and maintains an active R&D pipeline of 50+ drugs, launching 10+ products annually and expanding into innovative drug development including non-hormonal dermatological topicals and CNS therapies.

Differentiator

Problem solved

Functional benefit

Products and services

• Akriderm (Акридерм) line Dermatological corticosteroid product line for treating inflammatory and allergic skin conditions, available in cream, ointment, solution, and combination variants (gentamicin, clotrimazole, salicylic acid).
• Akvadetrim (Аквадетрим) Vitamin D3 (cholecalciferol) supplement for preventing and treating vitamin D deficiency, available as oral drops (15,000 IU/ml) and soluble tablets (500/1,000/2,000 IU).
• Azelik (Азелик) Azelaic acid-based topical gel (15%) for treating acne and rosacea.
• Akriol Pro (Акриол Про) Topical anesthetic cream (2.5% lidocaine + 2.5% prilocaine) for skin anesthesia procedures.
• Phytolysin (Фитолизин) Herbal diuretic product for treating urinary tract infections and nephrourolithiasis, available as oral paste (100g) and capsules (40 pcs).
• Phytolysin PRENATAL (Фитолизин ПРЕНАТАЛ) Dietary supplement (BAD) variant of Phytolysin formulated for use during pregnancy, supporting kidney and urinary tract function.
• Phytolysin nefroCAPS (Фитолизин нефроКАПС) Dietary supplement (BAD) in capsule form containing dry plant extracts, a source of flavonoids for maintaining normal kidney and urinary tract function.
• Broncho-Vaxom Junior (Бронхо-Ваксом детский) Immunostimulant capsules for children containing bacterial lysates (3.5 mg) to prevent recurrent respiratory tract infections.
• Clindacin (Клиндацин) Antibiotic lincomoside vaginal suppositories (100 mg clindamycin phosphate) for treating bacterial vaginosis.
• Clindovit (Клиндовит) Topical antibiotic gel (1% clindamycin) for treating acne vulgaris.
• Mycosoral (Микозорал) Topical antifungal ointment (2% ketoconazole) for treating skin mycoses, dermatophytosis, candidiasis, pityriasis versicolor, and seborrheic dermatitis.
• Comfoderm (Комфодерм) line Topical methylprednisolone aceponate corticosteroid line for inflammatory skin diseases, with cream, ointment, ceramides-enriched cream (K), and urea-enriched cream (M2) variants.
• Pantoderm (Пангодерм) Tissue repair stimulant cream containing dexpanthenol (5%) for wound healing, burn treatment, skin barrier protection, and nursing/nipple care.
• Ovipol Clio (Овипол Клио) Vaginal estrogen suppositories (0.5 mg estriol) for hormone replacement therapy treating urogenital atrophy, vulvovaginal atrophy, and menopausal symptoms.
• Dinobutin (Динобутин) Oral gel (8.9 mg/g trimebutine maleate) for functional GI disorders including IBS, functional dyspepsia, gallbladder dysfunction, and post-cholecystectomy syndrome; indicated for adults and children from age 3.
• Sitagliptin + Metformin combination (Ситаглиптин + Метформин) Combined diabetes medication pairing DPP-4 inhibitor sitagliptin with extended-release metformin, unique for the Russian market, launched 2025-2026.
• Espiro (Эспиро) Mineralocorticoid receptor antagonist (25/50 mg eplerenone) for treating heart failure post-myocardial infarction and chronic heart failure (NYHA Class II).
• Fonturacetam-Akrikhin (Фонтурацетам-Акрихин) Nootropic and psychostimulant tablets (100 mg) for treating CNS disorders, memory/cognitive impairment, cerebrovascular insufficiency, obesity, and chronic alcoholism.
• Fordiglif (dapagliflozin generic) Generic dapagliflozin drug competing with AstraZeneca's Forxiga for treating type 2 diabetes; right to sell in Russia upheld by Russian Supreme Court in July 2026.
• MNN-Akrikhin (МНН-Акрихин) generic portfolio Generic drug sub-brand under MNN (international non-proprietary name) branding covering the company's full therapeutic portfolio across dermatology, cardiology, neurology, gynecology, and gastroenterology.
• Giposart (Гипосарт) line Cardiovascular drug line based on candesartan (angiotensin II receptor antagonist) with combination variants: Giposart A (candesartan + amlodipine), Giposart I (candesartan + indapamide), Giposart N (candesartan + hydrochlorothiazide).
• Glidiab / Glidiab MV (Глидиаб / Глидиаб МВ) Sulfonylurea oral hypoglycemic agents for type 2 diabetes: Glidiab (gliclazide 80 mg standard release) and Glidiab MV (gliclazide 30 mg modified release).
• Glimecomb (Глимекомб) Fixed-dose combination of glimepiride (40 mg) + metformin (500 mg) for type 2 diabetes treatment.
• Insudayv (Инсудайв) / Insudayv Slim (Инсудайв слим) Insulin products: Insudayv (0.25/0.5/1 mg/dose solution for injection) and Insudayv Slim (broader dosing range including 1.7 mg and 2.4 mg for improved glycemic control).
• Kapozid (Капозид) Fixed-dose antihypertensive combination: captopril 25 mg + hydrochlorothiazide 50 mg.
• Diaglinid (Диаглинид) Meglitinide class oral hypoglycemic agent (repaglinide 1 mg) for type 2 diabetes, stimulating early-phase insulin secretion.
• Zinakoren (Зинакорен) Calcium channel blocker (2.5/10/15/20 mg) for treating cardiovascular conditions.
• Akrivario (Акриварио) Antiviral drug (50/100/200 mg) for treating viral infections.
• Menoril (Менорил) / Menoril Plus (Менорил плюс) Dietary supplement (BAD) capsules for women's health, providing phytoestrogen support (genistein); Menoril Plus is an enhanced formulation with higher dosage.
• Normobakt L (Нормобакт Л) Probiotic powder for preparing suspension (3g, 10 sachets) containing Lactobacillus rhamnosus for restoring gut microflora.
• SuperOptic (СуперОптик) Dietary supplement (BAD) capsules (850 mg, 60 capsules) for eye health and vision support, containing lutein and other carotenoids.
• Contract manufacturing services GMP-certified contract manufacturing services offered to other pharmaceutical companies seeking reliable production capacity in Russia, marketed via [email protected].

Quantifiable outcome

• 10+ new drugs launched into commercial production annually
• +4 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

Feature4 records

Partnerships

Two partnerships are on record, tiered minor.

• Club of Investors of the Pharmaceutical and Medical Industry (Клуб инвесторов фармацевтической и медицинской промышленности)minorOthersAkrikhin joined the Club of Investors of the Pharmaceutical and Medical Industry, an association created in 2011 to attract private capital to the Russian pharmaceutical and medical industry. The club develops investment climate in healthcare, supports industry projects, strengthens links between investors, manufacturers, scientific and educational organizations, and facilitates best practice exchange. Akrikhin's 90 years of accumulated expertise is expected to strengthen the club's work on pharmaceutical industry projects in Russia.
• AstraZeneca (patent dispute opponent — adversarial, not partnership)minorOthersAkrikhin was involved in a patent dispute with UK pharma major AstraZeneca over dapagliflozin (Forxiga). The Russian Supreme Court upheld the Intellectual Property Court's ruling in Akrikhin's favor, ordering AstraZeneca to refrain from actions preventing Akrikhin's competing generic drug Fordiglif from being sold in the Russian market. This was a legal dispute, not a commercial partnership.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• KRKA: Slovenian-headquartered generic pharmaceutical manufacturer with significant operations in Russia. Direct competitor in Russian ЖНВЛП tenders and pharmacy retail, but at substantially larger scale and broader European footprint than Akrikhin.
• Sandoz (Novartis): Global generic and biosimilar pharmaceutical company spun out of Novartis, with established Russian commercial presence. Comparable to Akrikhin in generic portfolio breadth and contract manufacturing capabilities, but at a much larger international scale.
• Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer, with active operations in Russia. Comparable to Akrikhin in generic portfolio breadth, but at vastly larger global scale and broader therapeutic reach.
• STADA Arzneimittel (Russia): German-headquartered generic pharmaceutical company with an established Russian commercial presence. Competes with Akrikhin across Russian generics and OTC categories, but as a much larger European incumbent with global manufacturing.

Direct peers

• Obolenskoe Pharmaceutical Enterprise: Russian pharmaceutical manufacturer of generic drugs across multiple therapeutic areas. Direct peer to Akrikhin in the domestic Russian generics market and government procurement channels.
• Valenta Pharm: Russian pharmaceutical company developing, manufacturing, and marketing branded and generic drugs in CNS, antibacterial, immunology, and urology. Comparable to Akrikhin in its branded-generic strategy and domestic Russian focus.
• Pharmstandard: Largest Russian pharmaceutical manufacturer, producing generics, OTC drugs, and biosimilars across cardiovascular, gastroenterology, and metabolic therapy areas. Direct competitor to Akrikhin in ЖНВЛП tenders and Russian pharmacy retail.
• Polysan: Russian pharmaceutical manufacturer specializing in antivirals, immunomodulators, and metabolic products. Comparable to Akrikhin as a domestic producer serving the Russian hospital and pharmacy channels.
• Sotex (SOТЕКС): Russian pharmaceutical manufacturer producing generic injectables and specialty products, part of the Pharmstandard group. Comparable to Akrikhin in domestic Russian generic manufacturing and government hospital supply.
• Vertex (Вертекс): Russian pharmaceutical manufacturer based in Saint Petersburg producing generics and OTC products in dermatology, neurology, gynecology, and respiratory categories. Closely comparable to Akrikhin in therapeutic breadth and domestic Russian generics focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/akrikhin.official
• LinkedInlinkedin.com/company/akrikhin-polpharma

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Akrikhin